Septerna, Inc. (SEPN)
| Market Cap | 1.09B |
| Revenue (ttm) | 45.95M |
| Net Income (ttm) | -48.88M |
| Shares Out | 44.91M |
| EPS (ttm) | -1.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,227 |
| Open | 25.09 |
| Previous Close | 25.09 |
| Day's Range | 23.95 - 25.51 |
| 52-Week Range | 6.42 - 32.63 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 38.14 (+57.12%) |
| Earnings Date | May 14, 2026 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM f... [Read more]
Financial Performance
In 2025, Septerna's revenue was $45.95 million, an increase of 4174.51% compared to the previous year's $1.08 million. Losses were -$48.88 million, -31.92% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SEPN stock is "Strong Buy." The 12-month stock price target is $38.14, which is an increase of 57.12% from the latest price.
News
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R ...
Septerna Transcript: TD Cowen 46th Annual Health Care Conference
SEP-631 showed strong phase I safety and efficacy, supporting once-daily dosing and a phase II trial in CSU later this year. SEP-479, an oral PTH agonist, is entering clinical trials after promising preclinical results. Chronic tox studies and additional indications are advancing.
Septerna Transcript: Study result
SEP-631 demonstrated a favorable safety profile and robust, dose-dependent inhibition of MRGPRX2 signaling in a phase I trial, supporting once-daily oral dosing without food restrictions. These results validate clinical proof of mechanism and support advancement into phase II studies for chronic spontaneous urticaria and other mast cell-driven diseases.
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses...
Septerna to Present at TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company leverages its Native Complex Platform to rapidly advance a diverse GPCR-targeted pipeline, with lead programs SEP-479 and SEP-631 progressing toward key clinical milestones. Strong financials, strategic collaborations, and robust IP underpin a focus on high unmet needs in endocrinology and immunology.
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company presented progress on its GPCR-focused pipeline, highlighting SEP-479 for hyperparathyroidism and SEP-631 for mast cell diseases, both advancing toward key clinical milestones in 2024. A TSHR NAM program is also progressing, with Graves' disease as the initial target.
Septerna to Participate in 8th Annual Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna Transcript: TD Cowen Immunology and Inflammation Summit
The summit highlighted progress on two lead programs: SEP-631, a once-daily oral MRGPRX2 inhibitor in phase I for mast cell diseases, and SEP-479, a PTH1 receptor agonist for hypoparathyroidism expected to enter the clinic next year. Additional pipeline and partnership updates were shared.
Septerna Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
A novel GPCR drug discovery platform is advancing multiple programs, including SEP-479 for hyperparathyroidism and SEP-631 for mast cell diseases, both with strong preclinical and early clinical progress. A major Novo Nordisk collaboration and robust cash position support continued pipeline growth.
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expe...
Septerna to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug dis...
Septerna Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
SEP-479, a next-generation PTH receptor agonist, showed strong preclinical efficacy and safety, with phase one trials planned for next year. SEP-631, targeting MRGPRX2, is in phase one with a broad indication strategy. A major Novo Nordisk partnership supports expansion into metabolic diseases.
Septerna Transcript: Cantor Global Healthcare Conference 2025
The presentation highlighted a robust GPCR-focused drug discovery platform, major updates on SEP-479 for hypoparathyroidism with improved efficacy and safety, and progress on SEP-631 for mast cell diseases. Strong financials and strategic partnerships support a broad, advancing pipeline.
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
On Monday, HC Wainwright initiated coverage on Septerna, Inc. SEPN, citing a next-generation drug design platform aimed at hitherto-undruggable targets.
Septerna Transcript: Jefferies Global Healthcare Conference 2025
The presentation highlighted a robust GPCR-focused drug discovery platform, with multiple programs advancing in endocrinology, immunology, and metabolic disease. Next-generation candidates are progressing toward clinical trials, and a major Novo Nordisk collaboration strengthens financial runway and R&D capacity.
Septerna to Present at Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ann...